Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 181
Filtrar
Más filtros

Medicinas Complementárias
Intervalo de año de publicación
1.
BMC Cancer ; 22(1): 220, 2022 Feb 28.
Artículo en Inglés | MEDLINE | ID: mdl-35227226

RESUMEN

BACKGROUND: Cancer patient pathways (CPPs) were implemented in Norway to reduce unnecessary waiting times, regional variations, and to increase the predictability of cancer care for the patients. This study aimed to determine if 70% of cancer patients started treatment within the recommended time frames, and to identify potential delays. METHODS: Patients registered with a colorectal, lung, breast, or prostate cancer diagnosis at the Cancer Registry of Norway in 2015-2016 were linked with the Norwegian Patient Registry and Statistics Norway. Adjusting for sociodemographic variables, multivariable quantile (median) regressions were used to examine the association between place of residence and median time to start of examination, treatment decision, and start of treatment. RESULTS: The study included 20 668 patients. The proportions of patients who went through the CPP within the recommended time frames were highest among colon (84%) and breast (76%) cancer patients who underwent surgery and lung cancer patients who started systemic anticancer treatment (76%), and lowest for prostate cancer patients who underwent surgery (43%). The time from treatment decision to start of treatment was the main source of delay for all cancers. Travelling outside the resident health trust prolonged waiting time and was associated with a reduced odds of receiving surgery and radiotherapy for lung and rectal cancer patients, respectively. CONCLUSIONS: Achievement of national recommendations of the CCP times differed by cancer type and treatment. Identified bottlenecks in the pathway should be targeted to decrease waiting times. Further, CPP guidelines should be re-examined to determine their ongoing relevance.


Asunto(s)
Vías Clínicas/estadística & datos numéricos , Neoplasias/terapia , Aceptación de la Atención de Salud/estadística & datos numéricos , Cooperación del Paciente/estadística & datos numéricos , Tiempo de Tratamiento/estadística & datos numéricos , Adulto , Anciano , Anciano de 80 o más Años , Vías Clínicas/normas , Femenino , Geografía , Humanos , Almacenamiento y Recuperación de la Información , Masculino , Persona de Mediana Edad , Noruega , Sistema de Registros , Factores de Tiempo , Tiempo de Tratamiento/normas , Listas de Espera
2.
Thromb Haemost ; 122(3): 406-414, 2022 03.
Artículo en Inglés | MEDLINE | ID: mdl-34020488

RESUMEN

OBJECTIVE: The 'Atrial fibrillation Better Care' (ABC) pathway has been recently proposed as a holistic approach for the comprehensive management of patients with atrial fibrillation (AF). We performed a systematic review of current evidence for the use of the ABC pathway on clinical outcomes. METHODS AND RESULTS: We performed a systematic review and meta-analysis according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. PubMed and EMBASE were searched for studies reporting the prevalence of ABC-pathway-adherent management in AF patients, and its impact on clinical outcomes (all-cause death, cardiovascular death, stroke, and major bleeding). Meta-analysis of odds ratio (OR) was performed with random-effects models; subgroup analysis and meta-regression were performed to account for heterogeneity. Among the eight studies included, we found a pooled prevalence of ABC-adherent management of 21% (95% confidence interval, CI: 13-34%), with a high grade of heterogeneity, explained by the increasing adherence to each ABC criterion. Patients treated according to the ABC pathway showed a lower risk of all-cause death (OR: 0.42; 95% CI: 0.31-0.56), cardiovascular death (OR: 0.37; 95% CI: 0.23-0.58), stroke (OR: 0.55; 95% CI: 0.37-0.82) and major bleeding (OR: 0.69; 95% CI: 0.51-0.94), with moderate heterogeneity. Prevalence of comorbidities was moderators of heterogeneity for all-cause and cardiovascular death, while longer follow-up was associated with increased effectiveness for all outcomes. CONCLUSION: Adherence to the ABC pathway was suboptimal, being adopted in one in every five patients. Adherence to the ABC pathway was associated with a reduction in the risk of major adverse outcomes.


Asunto(s)
Anticoagulantes/uso terapéutico , Fibrilación Atrial , Vías Clínicas , Hemorragia , Accidente Cerebrovascular , Fibrilación Atrial/complicaciones , Fibrilación Atrial/tratamiento farmacológico , Vías Clínicas/organización & administración , Vías Clínicas/normas , Adhesión a Directriz/estadística & datos numéricos , Hemorragia/inducido químicamente , Hemorragia/prevención & control , Humanos , Guías de Práctica Clínica como Asunto , Accidente Cerebrovascular/etiología , Accidente Cerebrovascular/prevención & control
4.
CMAJ Open ; 9(4): E1120-E1127, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34848553

RESUMEN

BACKGROUND: Delays in cancer diagnosis have been associated with reduced survival, decreased quality of life after treatment, and suboptimal patient experience. The objective of the study was to explore the perspectives of a group of family physicians and other specialists regarding potentially avoidable delays in diagnosing cancer, and approaches that may help expedite the process. METHODS: We conducted a qualitative study using interviews with physicians practising in primary and outpatient care settings in Alberta between July and September 2019. We recruited family physicians and specialists who were in a position to discuss delays in cancer diagnosis by email via the Cancer Strategic Clinical Network and the Alberta Medical Association. We conducted semistructured interviews over the phone, and analyzed data using thematic analysis. RESULTS: Eleven family physicians and 22 other specialists (including 7 surgeons or surgical oncologists, 3 pathologists, 3 radiologists, 2 emergency physicians and 2 hematologists) participated in interviews; 22 were male (66.7%). We identified 4 main themes describing 9 factors contributing to potentially avoidable delays in diagnosis, namely the nature of primary care, initial presentation, investigation, and specialist advice and referral. We also identified 1 theme describing 3 suggestions for improvement, including system integration, standardized care pathways and a centralized advice, triage and referral support service for family physicians. INTERPRETATION: These findings suggest the need for enhanced support for family physicians, and better integration of primary and specialty care before cancer diagnosis. A multifaceted and coordinated approach to streamlining cancer diagnosis is required, with the goals of enhancing patient outcomes, reducing physician frustration and optimizing efficiency.


Asunto(s)
Vías Clínicas/normas , Diagnóstico Tardío/prevención & control , Neoplasias , Médicos de Familia/estadística & datos numéricos , Atención Primaria de Salud , Especialización/estadística & datos numéricos , Triaje , Alberta/epidemiología , Prestación Integrada de Atención de Salud/métodos , Necesidades y Demandas de Servicios de Salud , Humanos , Neoplasias/diagnóstico , Neoplasias/terapia , Rol del Médico , Atención Primaria de Salud/métodos , Atención Primaria de Salud/organización & administración , Atención Primaria de Salud/normas , Investigación Cualitativa , Mejoramiento de la Calidad , Derivación y Consulta/organización & administración , Tiempo de Tratamiento/normas , Triaje/organización & administración , Triaje/normas
6.
BMC Pregnancy Childbirth ; 21(1): 320, 2021 Apr 22.
Artículo en Inglés | MEDLINE | ID: mdl-33888075

RESUMEN

BACKGROUND: Postpartum hemorrhage (PPH) is the leading cause of maternal mortality in low-income countries, and is the most common direct cause of maternal deaths in Madagascar. Studies in Madagascar and other low-income countries observe low provider adherence to recommended practices for PPH prevention and treatment. Our study addresses gaps in the literature by applying a behavioral science lens to identify barriers inhibiting facility-based providers' consistent following of PPH best practices in Madagascar. METHODS: In June 2019, we undertook a cross-sectional qualitative research study in peri-urban and rural areas of the Vatovavy-Fitovinany region of Madagascar. We conducted 47 in-depth interviews in 19 facilities and five communities, with facility-based healthcare providers, postpartum women, medical supervisors, community health volunteers, and traditional birth attendants, and conducted thematic analysis of the transcripts. RESULTS: We identified seven key behavioral insights representing a range of factors that may contribute to delays in appropriate PPH management in these settings. Findings suggest providers' perceived low risk of PPH may influence their compliance with best practices, subconsciously or explicitly, and lead them to undervalue the importance of PPH prevention and monitoring measures. Providers lack clear feedback on specific components of their performance, which ultimately inhibits continuous improvement of compliance with best practices. Providers demonstrate great resourcefulness while operating in a challenging context with limited equipment, supplies, and support; however, overcoming these challenges remains their foremost concern. This response to chronic scarcity is cognitively taxing and may ultimately affect clinical decision-making. CONCLUSIONS: Our study reveals how perception of low risk of PPH, limited feedback on compliance with best practices and consequences of current practices, and a context of scarcity may negatively affect provider decision-making and clinical practices. Behaviorally informed interventions, designed for specific contexts that care providers operate in, can help improve quality of care and health outcomes for women in labor and childbirth.


Asunto(s)
Vías Clínicas/normas , Servicios de Salud Materna , Hemorragia Posparto , Gestión de Riesgos , Adulto , Actitud del Personal de Salud , Femenino , Adhesión a Directriz/estadística & datos numéricos , Humanos , Madagascar/epidemiología , Servicios de Salud Materna/normas , Servicios de Salud Materna/estadística & datos numéricos , Mortalidad Materna , Partería , Prioridad del Paciente , Hemorragia Posparto/mortalidad , Hemorragia Posparto/prevención & control , Hemorragia Posparto/terapia , Embarazo , Investigación Cualitativa , Gestión de Riesgos/métodos , Gestión de Riesgos/estadística & datos numéricos , Percepción Social , Tiempo de Tratamiento/normas , Tiempo de Tratamiento/estadística & datos numéricos
7.
J Drugs Dermatol ; 20(2): 134-142, 2021 02 01.
Artículo en Inglés | MEDLINE | ID: mdl-33538559

RESUMEN

BACKGROUND: Impetigo, a highly contagious bacterial skin infection commonly occurring in young children, but adults may also be affected. The superficial skin infection is mainly caused by Staphylococcus aureus (S. aureus) and less frequently by Streptococcus pyogenes (S. pyogenes). Antimicrobial resistance has become a worldwide concern and needs to be addressed when selecting treatment for impetigo patients. An evidence-based impetigo treatment algorithm was developed to address the treatment of impetigo for pediatric and adult populations. METHODS: An international panel of pediatric dermatologists, dermatologists, pediatricians, and pediatric infectious disease specialists employed a modified Delphi technique to develop the impetigo treatment algorithm. Treatment recommendations were evidence-based, taking into account antimicrobial stewardship and the increasing resistance to oral and topical antibiotics. RESULTS: The algorithm includes education and prevention of impetigo, diagnosis and classification, treatment measures, and follow-up and distinguishes between localized and widespread or epidemic outbreaks of impetigo. The panel adopted the definition of localized impetigo of fewer than ten lesions and smaller than 36 cm2 area affected in patients of two months and up with no compromised immune status. Resistance to oral and topical antibiotics prescribed for the treatment of impetigo such as mupirocin, retapamulin, fusidic acid, have been widely reported. CONCLUSIONS: When prescribing antibiotics, it is essential to know the local trends in antibiotic resistance. Ozenoxacin cream 1% is highly effective against S. pyogenes and S. aureus, including methycyllin-susceptible and resistant strains (MRSA), and may be a suitable option for localized impetigo.J Drugs Dermatol. 2021;20(2):134-142. doi:10.36849/JDD.5475 THIS ARTICLE HAD BEEN MADE AVAILABLE FREE OF CHARGE. PLEASE SCROLL DOWN TO ACCESS THE FULL TEXT OF THIS ARTICLE WITHOUT LOGGING IN. NO PURCHASE NECESSARY. PLEASE CONTACT THE PUBLISHER WITH ANY QUESTIONS.


Asunto(s)
Antibacterianos/uso terapéutico , Vías Clínicas/normas , Impétigo/tratamiento farmacológico , Staphylococcus aureus/efectos de los fármacos , Streptococcus pyogenes/efectos de los fármacos , Aminopiridinas/farmacología , Aminopiridinas/uso terapéutico , Antibacterianos/farmacología , Programas de Optimización del Uso de los Antimicrobianos/normas , Compuestos Bicíclicos Heterocíclicos con Puentes/farmacología , Compuestos Bicíclicos Heterocíclicos con Puentes/uso terapéutico , Técnica Delphi , Diterpenos/farmacología , Diterpenos/uso terapéutico , Farmacorresistencia Bacteriana , Medicina Basada en la Evidencia/normas , Ácido Fusídico/farmacología , Ácido Fusídico/uso terapéutico , Humanos , Impétigo/diagnóstico , Impétigo/microbiología , Pruebas de Sensibilidad Microbiana/normas , Mupirocina/farmacología , Mupirocina/uso terapéutico , Guías de Práctica Clínica como Asunto , Quinolonas/farmacología , Quinolonas/uso terapéutico , Crema para la Piel/farmacología , Crema para la Piel/uso terapéutico , Staphylococcus aureus/aislamiento & purificación , Streptococcus pyogenes/aislamiento & purificación , Revisiones Sistemáticas como Asunto
8.
Am J Clin Dermatol ; 22(2): 205-220, 2021 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-33492611

RESUMEN

Mastocytosis is a heterogeneous group of disorders characterized by the accumulation of clonal mast cells in organs such as the skin and bone marrow. In contrast to adults, most affected children have only cutaneous involvement. This article reviews the molecular pathogenesis, skin findings, mast cell mediator-related symptoms, evaluation, and management of childhood-onset mastocytosis, noting differences from adult-onset disease. Current classification of cutaneous mastocytosis and the natural histories of different variants in pediatric patients are highlighted, with a focus on clinical manifestations with prognostic implications. A practical algorithm is provided to guide clinical assessment, laboratory and other investigations, and longitudinal monitoring, including recognition of hepatosplenomegaly as a marker of systemic disease and utilization of allele-specific quantitative PCR (ASqPCR) to detect KIT mutations in the peripheral blood. Updated information and consensus-based recommendations regarding possible triggers of mast-cell degranulation (e.g., physical, medications) are discussed, with an emphasis on patient-specific factors and avoiding excessive parental concern. Lastly, an individualized, stepwise approach to treatment of symptoms, skin-directed therapy, and potential use of kinase inhibitors for severe systemic disease is outlined.


Asunto(s)
Vías Clínicas/normas , Mastocitos/patología , Mastocitosis Cutánea/diagnóstico , Inhibidores de Proteínas Quinasas/uso terapéutico , Piel/patología , Adulto , Factores de Edad , Biomarcadores/análisis , Degranulación de la Célula , Niño , Consenso , Dermatología/métodos , Dermatología/normas , Progresión de la Enfermedad , Humanos , Mastocitosis Cutánea/genética , Mastocitosis Cutánea/patología , Mastocitosis Cutánea/terapia , Mutación , Guías de Práctica Clínica como Asunto , Pronóstico , Índice de Severidad de la Enfermedad , Resultado del Tratamiento
9.
Urolithiasis ; 49(2): 167-172, 2021 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-32839877

RESUMEN

To demonstrate the feasibility of applying multiple-tract percutaneous nephrolithotomy (PCNL) as an overnight surgery for treatment of complex kidney stones. We reviewed a prospectively collected database of all multiple-tract PCNL planned as overnight surgery performed by a single surgeon since 2018. A clinical pathway including the removal of nephrostomy tube and discharge on the morning after surgery was carried out. A definition for tube removal was outlined. Ability to adhere to the pathway and achieving the described parameters and whether any resulting complications occurred were determined. A total of 136 consecutive patients were enrolled with mean stone burden of 960.5 mm2 and 5.1 cm. Mean operative time was 71.7 ± 30.7 min. The average hemoglobin drop was 17.6 ± 12.2 g/L, and the incidence of drop > 25 g/L was 21.9%. Overall, 125 patients (91.9%) but 11 patients were discharge on postoperative day 1. One case required readmission. Among the 11 patients, 7 patients (5.1%) underwent a delayed tube removal (≥ 2 days) and 4 patients underwent complications after next-day nephrostomy tube removal, including renal colic (2 cases), hydrothorax (1 case), and fever (1 case). Postoperative fever or severe hematuria was the major reason for delayed nephrostomy tube removal. The total complication rate was 8.8% (n = 12). Multiple-tract PCNL as an overnight surgery can be safely performed by experienced surgeons in most patients. An early nephrostomy tube removal could be achieved in nearly 95% patients.


Asunto(s)
Hematuria/epidemiología , Nefrolitotomía Percutánea/métodos , Nefrostomía Percutánea/métodos , Hemorragia Posoperatoria/epidemiología , Cálculos Coraliformes/cirugía , Adulto , Anciano , Vías Clínicas/normas , Estudios de Factibilidad , Femenino , Hematuria/diagnóstico , Hematuria/etiología , Hematuria/orina , Hemoglobinas/análisis , Humanos , Incidencia , Tiempo de Internación/estadística & datos numéricos , Masculino , Persona de Mediana Edad , Nefrolitotomía Percutánea/efectos adversos , Nefrostomía Percutánea/efectos adversos , Tempo Operativo , Readmisión del Paciente/estadística & datos numéricos , Atención Perioperativa/normas , Hemorragia Posoperatoria/sangre , Hemorragia Posoperatoria/diagnóstico , Hemorragia Posoperatoria/etiología , Estudios Prospectivos , Cálculos Coraliformes/diagnóstico , Resultado del Tratamiento
10.
Rev. medica electron ; 42(6): 2474-2486, nov.-dic. 2020. tab
Artículo en Español | LILACS, CUMED | ID: biblio-1150031

RESUMEN

RESUMEN Introducción: desde los finales del año pasado en Wuhan, se informó de una neumonía de etiología desconocida, que llevó a la Organización Mundial de la Salud a declarar la infección por SARS-CoV-2, como una emergencia sanitaria denominándola como enfermedad por coronavirus 2019 (COVID-19). En Cuba se confeccionó un programa de enfrentamiento, en el cual la atención hospitalaria, siguió un riguroso protocolo de atención a pacientes positivos de la COVID-19, en áreas de cuidados mínimos, intensivos o progresivos. Objetivo: caracterizar clínica/epidemiológica pacientes positivos de la COVID-19, ingresados en el Hospital "Amalia Simoni". Materiales y métodos: se realizó un estudio descriptivo, transversal de 1 066 ingresos en el Hospital "Amalia Simoni", de marzo-mayo del 2020. Se revisaron historias clínicas y se obtuvo: edad, sexo, procedencia, sintomatología, comorbilidades y evolución epidemiológica. Datos que se evaluaron mediante estadísticas descriptivas. Resultados: se halló un predominio de edad media, sin diferencias de sexo, predominaron los casos de la ciudad de Camagüey y de los municipios con mayor urbanización. Prevalecieron la tos y la fiebre, además de la mitad de los casos sin comorbilidades, con solo un pequeño porcentaje de casos confirmados. Conclusiones: con un enfoque basado en la medicina preventiva en los casos estudiados, predominó la edad media, de procedencia de áreas urbanizadas con mayor población y aglomeraciones sociales. Se destacó que el ingreso precoz, basada en la pesquisa de la Atención Primaria logró disminuir los casos confirmados a un pequeño porcentaje, al igual que los graves y un solo fallecido (AU).


ABSTRACT Introduction: from the end of the last year in Wuhan, China, it was informed an unknown etiology pneumonia leading the World Health Organization to declare the infection with SARS-CoV-2 a sanitary emergency naming it coronavirus disease 2019 (Covid-19). A confrontation program was elaborated in Cuba, in which hospital care followed a rigorous protocol to take care to Covid-19-positive patients in areas of minimal, intensive and progressive care. Objective: to clinically/epidemiologically characterize Covid-19-positive patients admitted in the Hospital "Amalia Simoni". Materials and methods: a cross-sectional, descriptive study was carried out in 1 066 patients admitted in the Hospital "Amalia Simoni" in the period March-May 2020. Clinical records were reviewed and data gathered were age, sex, origin, symptomatology, co-morbidities and epidemiological evolution, data obtained through descriptive statistics. Results: it was found the predominance of medium age, without sex differences; the cases of patients from the city of Camaguey and from the municipalities with biggest urbanization predominated. Cough and fever prevailed; half of cases did not have comorbidities, and only a little percent of cases was confirmed. Conclusions: with an approach based in preventive medicine, medium age, and provenance from urban areas with bigger population and social concentrations predominated in the studied cases. It was showed that precocious admission, based on the Primary Health Care screening, succeeded in diminish confirmed cases to a little percent, as diminished the seriously ill ones; only one patient died (AU).


Asunto(s)
Humanos , Masculino , Femenino , Pacientes , Infecciones por Coronavirus/epidemiología , Vías Clínicas/normas , Aislamiento de Pacientes/métodos , Signos y Síntomas , Evolución Clínica , Sensibilidad y Especificidad , Infecciones por Coronavirus/complicaciones , Infecciones por Coronavirus/diagnóstico
11.
Indian J Tuberc ; 67(4): 502-508, 2020 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-33077051

RESUMEN

BACKGROUND: The delay in the diagnosis and treatment initiation of patients with MDR-TB worsens individual prognosis and increases the risk of disease transmission in the community. These delays have been attributed to delay in treatment-seeking by the patient and shifting to multiple healthcare facilities before being tested and diagnosed through India's National Tuberculosis Elimination Program (NTEP). OBJECTIVE: to identify treatment pathways in patients with MDR-TB from the time of onset of symptoms and treatment seeking until diagnosis at a PMDT site and subsequent treatment initiation. We also compared these characteristics with those of patients with DS-TB. METHODS: We recruited a total of 168 patients with MDR-TB and DS-TB each, in Delhi. Data were analyzed using IBM SPSS Version 25. RESULTS: The mean (SD) patient delay for initial treatment-seeking was 20.9 (15.9) days in patients with MDR-TB, and 16.1 (17.1) days in patients with DS-TB (p < 0.001). The median time from visit to the first healthcare facility (HCF) until confirmation of MDR-TB diagnosis was 78.5 days, and until treatment initiation was 102.5 days. Among patients with DS-TB, the time interval from a visit to the first HCF until the initiation of ATT-DOTS was 61.5 days.. Patients diagnosed with DS-TB, whose first source of treatment was a private facility (n = 49), reported a significant delay in the initiation of ATT-DOTS (p < 0.001). CONCLUSIONS: Despite the introduction of universal drug sensitivity testing in individuals having presumptive MDR-TB, a significant delay in the diagnosis and initiation of effective MDR-TB treatment persists as a major public health challenge in India.


Asunto(s)
Antituberculosos/uso terapéutico , Vías Clínicas , Diagnóstico Tardío , Pruebas de Sensibilidad Microbiana , Mycobacterium tuberculosis , Tiempo de Tratamiento , Tuberculosis Resistente a Múltiples Medicamentos , Adulto , Vías Clínicas/organización & administración , Vías Clínicas/normas , Diagnóstico Tardío/efectos adversos , Diagnóstico Tardío/prevención & control , Transmisión de Enfermedad Infecciosa/prevención & control , Femenino , Necesidades y Demandas de Servicios de Salud , Humanos , India/epidemiología , Masculino , Pruebas de Sensibilidad Microbiana/métodos , Pruebas de Sensibilidad Microbiana/tendencias , Mycobacterium tuberculosis/efectos de los fármacos , Mycobacterium tuberculosis/aislamiento & purificación , Aceptación de la Atención de Salud , Pronóstico , Tiempo de Tratamiento/organización & administración , Tiempo de Tratamiento/normas , Tuberculosis Resistente a Múltiples Medicamentos/diagnóstico , Tuberculosis Resistente a Múltiples Medicamentos/epidemiología , Tuberculosis Resistente a Múltiples Medicamentos/terapia , Tuberculosis Resistente a Múltiples Medicamentos/transmisión
14.
Hepatology ; 72(6): 2206-2218, 2020 12.
Artículo en Inglés | MEDLINE | ID: mdl-32064645

RESUMEN

Treatment allocation is extremely complex in patients with hepatocellular carcinoma (HCC) because this neoplasm arises, in most cases, in patients with cirrhosis and additional comorbidities. The "stage hierarchy" approach, which involves linking each stage (or substage) of the disease to a specific treatment, has become the main proposed treatment strategy for the clinical management of HCC, particularly in the West. The Barcelona Clinic Liver Cancer (BCLC) scheme serves as the main example of the application of this strategy. In an attempt to increase the plasticity of the "stage hierarchy" approach as well as its adaptability to the requirements of real-world clinical practice, the latest versions of European and American guidelines have introduced certain relevant elements of flexibility, which were not intrinsic to the original BCLC scheme. These elements are as follows: the "treatment stage migration" strategy, which allows moving to another treatment (generally the one that is associated with the subsequent stage) if the approach linked with the current stage proves to be unfeasible, and the "treatment stage alternative" approach, which proposes further therapeutic options for each BCLC-defined stage. In regard to most of the solid cancers, another potential strategy is to consider the treatment decision to be hierarchically dictated by the efficacy of each therapy with complete or partial independence from the tumor stage. This concept of "therapeutic hierarchy" has been historically endorsed by the Asia-Pacific treatment algorithm as well as by the recent Italian multisociety guidelines. The present review provides a critical analysis of the different conceptual approaches to HCC management, highlighting their advantages and disadvantages and focusing on the remarkable differences between the stage-guided and the hierarchical strategies.


Asunto(s)
Carcinoma Hepatocelular/terapia , Vías Clínicas/tendencias , Neoplasias Hepáticas/terapia , Oncología Médica/tendencias , Guías de Práctica Clínica como Asunto , Carcinoma Hepatocelular/diagnóstico , Carcinoma Hepatocelular/mortalidad , Reglas de Decisión Clínica , Vías Clínicas/normas , Humanos , Neoplasias Hepáticas/diagnóstico , Neoplasias Hepáticas/mortalidad , Oncología Médica/métodos , Oncología Médica/normas , Estadificación de Neoplasias , Selección de Paciente , Pronóstico , Medición de Riesgo/métodos , Medición de Riesgo/normas , Resultado del Tratamiento
15.
J Clin Endocrinol Metab ; 105(3)2020 03 01.
Artículo en Inglés | MEDLINE | ID: mdl-31665485

RESUMEN

CONTEXT: The improved remission and complication rates of current transsphenoidal surgery warrant reappraisal of the position of surgery as a viable alternative to dopamine agonists in the treatment algorithm of prolactinomas. OBJECTIVE: To compare clinical outcomes after dopamine agonist withdrawal and transsphenoidal surgery in prolactinoma patients. METHODS: Eight databases were searched up to July 13, 2018. Primary outcome was disease remission after drug withdrawal or surgery. Secondary outcomes were biochemical control and side effects during dopamine agonist treatment and postoperative complications. Fixed- or random-effects meta-analysis was performed to estimate pooled proportions. Robustness of results was assessed by sensitivity analyses. RESULTS: A total of 1469 articles were screened: 55 (10 low risk of bias) on medical treatment (n = 3564 patients) and 25 (12 low risk of bias) on transsphenoidal surgery (n = 1836 patients). Long-term disease remission after dopamine agonist withdrawal was 34% (95% confidence interval [CI], 26-46) and 67% (95% CI, 60-74) after surgery. Subgroup analysis of microprolactinomas showed 36% (95% CI, 21-52) disease remission after dopamine agonist withdrawal, and 83% (95% CI, 76-90) after surgery. Biochemical control was achieved in 81% (95% CI, 75-87) of patients during dopamine agonists with side effects in 26% (95% CI, 13-41). Transsphenoidal surgery resulted in 0% mortality, 2% (95% CI, 0-5) permanent diabetes insipidus, and 3% (95% CI, 2-5) cerebrospinal fluid leakage. Multiple sensitivity analyses yielded similar results. CONCLUSIONS: In the majority of prolactinoma patients, disease remission can be achieved through surgery, with low risks of long-term surgical complications, and disease remission is less often achieved with dopamine agonists.


Asunto(s)
Vías Clínicas/normas , Agonistas de Dopamina/uso terapéutico , Hipofisectomía/métodos , Microcirugia/métodos , Neoplasias Hipofisarias/terapia , Prolactinoma/terapia , Agonistas de Dopamina/farmacología , Agonistas de Dopamina/normas , Femenino , Humanos , Hipofisectomía/efectos adversos , Hipofisectomía/normas , Microcirugia/efectos adversos , Microcirugia/normas , Hipófisis/efectos de los fármacos , Hipófisis/metabolismo , Hipófisis/patología , Hipófisis/cirugía , Neoplasias Hipofisarias/patología , Guías de Práctica Clínica como Asunto , Prolactina/metabolismo , Prolactinoma/patología , Inducción de Remisión/métodos , Estudios Retrospectivos , Resultado del Tratamiento
16.
Chest ; 157(4): 955-965, 2020 04.
Artículo en Inglés | MEDLINE | ID: mdl-31738929

RESUMEN

BACKGROUND: Treatment of pulmonary arterial hypertension (PAH) has evolved substantially over the past two decades and varies according to etiology, functional class (FC), hemodynamic parameters, and other clinical factors. Current guidelines do not provide definitive recommendations regarding the use of oral prostacyclin pathway agents (PPAs) in PAH. To provide guidance on the use of these agents, an expert panel was convened to develop consensus statements for the initiation of oral PPAs in adults with PAH. METHODS: A systematic literature search was conducted using MEDLINE. The established RAND/University of California Los Angeles appropriateness method, which incorporates the Delphi method and the nominal group technique, was used to create consensus statements. Idiopathic, heritable, repaired congenital heart defect, and drug- or toxin-induced PAH (IPAH+) was considered as one etiologic grouping. The process was focused on the use of oral treprostinil or selexipag in patients with IPAH+ or connective tissue disease-associated PAH and FC II or III symptoms receiving background dual endothelin receptor antagonist/phosphodiesterase type 5 inhibitor therapy. RESULTS: The panel developed 14 consensus statements regarding the appropriate use of oral PPAs in the target population. The panel identified 13 clinical scenarios in which selexipag may be considered as a treatment option. CONCLUSIONS: The paucity of clinical evidence overall, and particularly from randomized trials in this setting, creates a gap in knowledge. These consensus statements are intended to aid physicians in navigating treatment options and using oral PPAs in the most appropriate manner in patients with PAH.


Asunto(s)
Epoprostenol , Hipertensión Arterial Pulmonar , Antihipertensivos/farmacología , Consenso , Vías Clínicas/normas , Epoprostenol/metabolismo , Epoprostenol/farmacología , Humanos , Evaluación de Necesidades , Hipertensión Arterial Pulmonar/etiología , Hipertensión Arterial Pulmonar/fisiopatología , Hipertensión Arterial Pulmonar/terapia
17.
J Cyst Fibros ; 19(3): 370-375, 2020 05.
Artículo en Inglés | MEDLINE | ID: mdl-31680041

RESUMEN

BACKGROUND: Antimicrobial susceptibility testing (AST) is a cornerstone of infection management in cystic fibrosis. However, there is little evidence that AST predicts the clinical outcome of CF antimicrobial treatment. It has been suggested there is a need for careful consideration of current AST use by the CF community. METHODS: We engaged a group of experts consisting of pulmonary (adult and pediatric) and infectious disease clinicians, microbiologists, and pharmacists representing a broad international experience. We conducted an iterative systematic survey (Delphi) to determine and quantify consensus regarding key questions facing CF clinicians in the use of respiratory culture results including what tests to order, when to obtain them, and how to act upon the results of the testing. RESULTS: Consensus was reached for many questions but there was not universal agreement to the questions that were addressed. There were some differences with respect to cultures obtained for surveillance compared to when there is clinical worsening. Areas of general consensus include when and how respiratory cultures should be performed, what information should be reported, and when AST should be performed. A key finding is that clinical response to treatment is used to guide treatment decisions rather than AST results. CONCLUSIONS: Recommendations are presented regarding questions related to microbiology testing for patients with CF. We have also offered recommendations for priority research questions.


Asunto(s)
Antibacterianos/uso terapéutico , Fibrosis Quística , Farmacorresistencia Bacteriana , Pruebas de Sensibilidad Microbiana/métodos , Utilización de Procedimientos y Técnicas , Adulto , Antibacterianos/clasificación , Niño , Consenso , Vías Clínicas/normas , Fibrosis Quística/tratamiento farmacológico , Fibrosis Quística/microbiología , Técnica Delphi , Humanos , Cooperación Internacional , Selección de Paciente , Resultado del Tratamiento
18.
Neurol Sci ; 41(4): 917-924, 2020 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-31836948

RESUMEN

Dementias are chronic, degenerative neurological disorders with a complex management that require the cooperation of different healthcare professionals. The Italian Ministry of Health produced the document "Guidance on Integrated Care pathway for People with Dementia" (GICPD) with the specific objective of providing a standardized framework for the definition, development, and implementation of integrated care pathways (ICP) dedicated to people with dementia. We searched all available Italian territorial ICPs. Two raters assessed the retrieved ICPs with a 2-point scale on a 43-item checklist based on the GICPD. Only 5 out of 21 regions and 5 out of 101 local health authorities had an ICP, with most ICPs having a moderate compliance to the GICPD, in particular for the items referring to the development and implementation of the care pathways. A low to moderate inter-rater agreement was observed, mainly due to a lack of standardized models to describe ICPs for dementias. Results suggest that policy- and decision-makers should pay more attention to the GICPD when producing ICPs. The direct communication with clinicians, and the implementation of more precise and appropriate clinical outcomes, could increase the involvement of clinicians, whose participation is crucial to guarantee that ICPs meet needs of patients and their carers.


Asunto(s)
Vías Clínicas/normas , Prestación Integrada de Atención de Salud/normas , Demencia/terapia , Adhesión a Directriz/normas , Guías como Asunto/normas , Evaluación de Procesos, Atención de Salud/normas , Lista de Verificación/estadística & datos numéricos , Vías Clínicas/estadística & datos numéricos , Prestación Integrada de Atención de Salud/estadística & datos numéricos , Adhesión a Directriz/estadística & datos numéricos , Humanos , Italia , Evaluación de Procesos, Atención de Salud/estadística & datos numéricos
19.
J. bras. pneumol ; 46(2): 1-11, 2020.
Artículo en Inglés | BIGG | ID: biblio-1291842

RESUMEN

Idiopathic pulmonary fibrosis (IPF) is a form of chronic interstitial lung disease of unknown cause, which predominantly affects elderly men who are current or former smokers. Even though it is an uncommon disease, it is of great importance because of its severity and poor prognosis. In recent decades, several pharmacological treatment modalities have been investigated for the treatment of this disease, and the classic concepts have therefore been revised. The purpose of these guidelines was to define evidence-based recommendations regarding the use of pharmacological agents in the treatment of IPF in Brazil. We sought to provide guidance on the practical issues faced by clinicians in their daily lives. Patients of interest, Intervention to be studied, Comparison of intervention and Outcome of interest (PICO)-style questions were formulated to address aspects related to the use of corticosteroids, N-acetylcysteine, gastroesophageal reflux medications, endothelin-receptor antagonists, phosphodiesterase-5 inhibitors, pirfenidone, and nintedanib. To formulate the PICO questions, a group of Brazilian specialists working in the area was assembled and an extensive review of the literature on the subject was carried out. Previously published systematic reviews with meta-analyses were analyzed for the strength of the compiled evidence, and, on that basis, recommendations were developed by employing the Grading of Recommendations Assessment, Development and Evaluation approach. The authors believe that the present document represents an important advance to be incorporated in the approach to patients with IPF, aiming mainly to improve its management, and can become an auxiliary tool for defining public policies related to IPF.


Asunto(s)
Humanos , Vías Clínicas/normas , Fibrosis Pulmonar Idiopática/tratamiento farmacológico , Acetilcisteína/uso terapéutico , Reflujo Gastroesofágico/tratamiento farmacológico , Corticoesteroides/uso terapéutico , Fibrosis Pulmonar Idiopática/diagnóstico , Inhibidores de Fosfodiesterasa 5/uso terapéutico , Antagonistas de los Receptores de Endotelina/uso terapéutico
20.
Jt Comm J Qual Patient Saf ; 45(12): 822-828, 2019 12.
Artículo en Inglés | MEDLINE | ID: mdl-31672660

RESUMEN

BACKGROUND: In 2018 the Agency for Healthcare Research and Quality (AHRQ) Evidence-based Practice Center (EPC) Program issued a call for strategies to disseminate AHRQ EPC systematic reviews. In this pilot, findings from the 2016 AHRQ EPC report on Clostridioides difficile infection were translated into a treatment pathway and disseminated via a cloud-based platform and electronic health record (EHR). METHODS: An existing 10-step framework was used for developing and disseminating evidence-based clinical pathways. The development of the EHR intervention was informed by the Five Rights model for clinical decision support and human-computer interaction design heuristics. The researchers used observations and time measurements to describe the impact of the EPC report on pathway development and examined provider adoption using counts of pathway views. RESULTS: Two main themes emerged: (1) discrepancies between the EPC report and existing guidelines prompted critical discussions about available treatments, and (2) lack of guideline and pathway syntheses in the EPC report necessitated a rapid literature review. Pathway development required 340 hours: 205 for the rapid literature review, 63 for pathway development and EHR intervention design, and 5 for technical implementation of the intervention. Pathways were viewed 1,069 times through the cloud-based platform and 47 times through a hyperlink embedded in key EHR ordering screens. CONCLUSION: Pathways can be an approach for disseminating AHRQ EPC report findings within health care systems; however, reports should include guideline and pathway syntheses to meet their full potential. Embedding hyperlinks to pathway content within the EHR may be a viable and low-effort solution for promoting awareness of evidence-based resources.


Asunto(s)
Infecciones por Clostridium/prevención & control , Vías Clínicas/organización & administración , Infección Hospitalaria/prevención & control , Registros Electrónicos de Salud/organización & administración , Mejoramiento de la Calidad/organización & administración , Clostridioides difficile , Nube Computacional , Vías Clínicas/normas , Registros Electrónicos de Salud/normas , Práctica Clínica Basada en la Evidencia , Proyectos Piloto , Mejoramiento de la Calidad/normas , Estados Unidos , United States Agency for Healthcare Research and Quality
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA